Steovit D3 1000mg/800E 84 tabk
Steovit D3 1000mg/800E 84 tabk
Steovit D3 1000mg/800E 84 tabk
Steovit D3 1000mg/800E 84 tabk

Steovit D3 1000mg/800E 84 tabk

NYCOMED BELGIUM
2562593
€37.86
Tax included

Therapeutic indications

 

Steovit D3 1000mg/800E 84 tabk

.

Therapeutic indications

Prevention and treatment of vitamin D and calcium deficiency in the elderly.
Vitamin D and calcium supplement, as an adjunct to specific treatment of osteoporosis in patients who are at risk of vitamin D and calcium deficiency.

Dosage and method of administration

Adults and elderly
A chewable tablet once a day. The tablet may be chewed or sucked.
Dosage in hepatic impairment
No dosage adjustment is required.
Dosage in renal impairment
Steovit D3 1000 mg/800 i.e. should not be used in patients with severe renal impairment.
Steovit D3 1000 mg/800 i.e. is not intended for use in children.

This is a medicine, no prolonged use without medical advice, keep away from children, read the leaflet carefully. Ask your doctor or pharmacist. In case of side effects, contact your doctor.


Contra-indications

• Diseases and / or conditions resulting in hypercalcaemia and / or hypercalciuria
• Nephrolithiasis
• hypervitaminosis D
• Hypersensitivity to soy or peanuts
• Hypersensitivity to the active substances or to any of the excipients

Special warnings and precautions for use

During prolonged treatment, the serum calcium and renal function should be monitored monitored by measurements of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see Section Interactions with other medicaments and other forms of interaction) and in patients with a high tendency to calculus formation. In case of hypercalcaemia or renal impairment the dose should be reduced or treatment should stop be put.
Vitamin D should be used with caution in patients with renal impairment and the impact on calcium and phosphate levels should be monitored. The risk of calcification of the soft tissues must be observed. In patients with severe renal insufficiency, vitamin D in the form of cholecalciferol not metabolised normally and other forms of vitamin D used (see Contraindications section).
Steovit D3 1000 mg/800 i.e. tablets should be prescribed with caution in patients suffering from sarcoidosis, because the risk of increased metabolism of vitamin D to its active form. In these patients, the calcium content in serum and urine checked.
Steovit D3 1000 mg/800 i.e. tablets should be used with caution in immobilized patients with osteoporosis due to increased risk of hypercalcaemia.
The content of vitamin D (800 IU) in Steovit D3 1000 IU mg/800 must be observed if other medicines based on vitamin D are prescribed. The intake of additional doses of calcium or vitamin D should be under close medical supervision. In such cases it is necessary to serum calcium and urinary excretion of calcium frequent monitoring.
Steovit D3 1000 mg/800 i.e. tablet contains aspartame ((E951), a source of phenylalanine). May be harmful for people with phenylketonuria.
Steovit D3 1000 mg/800 i.e. tablets contain sorbitol (E420), isomalt (E953) and sucrose. Patients with rare hereditary disorder of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Interaction with other medicinal products and other forms of interaction

The thiazide diuretics reduce the urinary excretion of calcium. Because of an increased risk of hypercalcaemia, serum calcium regularly monitored during concomitant use of thiazide diuretics.
Systemic corticosteroids reduce calcium absorption. During concomitant use, the dose may be necessary Steovit D3 1000 IU mg/800 increase.
Simultaneous treatment with ion exchange resins such as cholestyramine or laxatives such as paraffin oil, the gastro-intestinal absorption of vitamin D decrease.
Calcium carbonate may interfere with the absorption of concomitantly administered tetracycline preparations. Therefore, tetracycline preparations at least two hours before or four to six hours after oral intake of calcium.
Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D increase. In these patients requires knowledge of the electrocardiogram (ECG) and serum calcium levels.
If a bisphosphonate or sodium fluoride is used concomitantly, this preparation should be at least 3 hours before the intake of Steovit D3 1000 IU mg/800 administered since the gastro-intestinal absorption may be reduced.
Oxalic acid (found in spinach and rhubarb) and phytic acid (found in whole cereals) may inhibit calcium absorption through the formation of insoluble complexes with calcium ions. The patients were not allowed to take calcium products within two hours after eating foods high in oxalic acid and phytic acid.

Pregnancy and lactation
Pregnancy
During pregnancy the daily intake should not exceed 1500 mg calcium and 600 IU vitamin D, and therefore Steovit D3 1000 IU mg/800 inappropriate during pregnancy. Animal studies showed reproductive toxicity of high doses of vitamin D. In pregnant women should have doses of calcium and vitamin D should be avoided as permanent hypercalcaemia has been related to adverse effects on the developing fetus.
Breastfeeding
Steovit D3 1000 mg/800 i.e. should be used during lactation. Calcium and vitamin D3 pass into breast milk. This should be considered when giving additional vitamin D is administered to the child.

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines. One effect is unlikely.

Side effects

Within each frequency grouping, undesirable effects of decreasing seriousness.
The side effects are listed below, by system organ class and frequency. Frequencies are defined as: Uncommon (> 1/1.000, <1 / 100), rare (> 1/10.000, <1/1.000) or very rare (<1/10.000).
Metabolism and nutrition disorders
Uncommon: Hypercalcaemia and hypercalciuria.
Gastrointestinal disorders
Rare: Constipation, flatulence, nausea, abdominal pain and diarrhea.
Skin and subcutaneous skin tissue disorders
Very rare: pruritus, rash and urticaria

Overdose

An overdose can lead to hypervitaminosis and hypercalcaemia. Symptoms of hypercalcaemia may include anorexia, thirst, nausea, vomiting, constipation, abdominal pain, muscle weakness, fatigue, mental disorders, polidipsie, polyuria, bone pain, nephrocalcinosis, kidney stones and in severe cases, cardiac arrhythmias. Extreme hypercalcaemia may result in coma and death. Persistently high calcium levels can lead to irreversible kidney damage and calcification of soft tissues.
Treatment of hypercalcaemia: treatment with calcium and vitamin D stop should be put. Treatment with thiazide diuretics, lithium, vitamin A, vitamin D and cardiac glycosides should also put to stop. Gastric Emptying in patients with impaired consciousness. Rehydration and, depending on the severity, isolated or combined treatment with loop diuretics, bisphosphonates, calcitonin and corticosteroids. The serum electrolytes, renal function and diuresis must be monitored. In severe cases, ECG and CVP should be.

Delivery form
Chewable Tablet
Type of product
Medicine
Brands
Steovit
No reviews

This is a medecine available without a prescription.. Do not use long without medical advice. Read the instructions carefully. Keep this medicine out of the reach of children. Keep the manual as it contains important information. Ask for advice from your doctor or pharmacist. Consult your doctor if adverse reactions.

'

16 other products in the same category:

Product added to wishlist
Product added to compare.

We use cookies to provide you with the best possible service. By visiting our website you agree to the placing of cookies.